secwatch / observer
8-K/A filed December 9, 2025, 6:59 PM ET ticker DMRA CIK 0001800315
regulatory confidence high sentiment neutral materiality 0.05

Galecto corrects Series C Preferred Stock authorization from 43,855 to 43,882 shares

Damora Therapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Damora Therapeutics, Inc.: Corrected authorized shares of Series C Preferred Stock from 43,855 to 43,882 (effective 2025-12-05).

Change
charter amendment
Effective
2025-12-05
Exact text from the filing
On December 5, 2025, the Company filed with the Delaware Secretary of State a Certificate of Correction (the “Certificate of Correction”) to the Certificate of Designation of Series C Preferred Stock to correct an inadvertent error in the number of shares of Series C Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the “Series C Preferred Stock”), that the Company is authorized to issue by modifying Section 2 of the Certificate of Designation of Series C Preferred Stock to correctly state that the number of authorized shares of Series C Preferred Stock is 43,882 shares instead of 43,855 shares.
View on SEC.gov

274 governance changes filed in the last 30 days. Browse all governance changes →

Damora Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-25-312912
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.